Advancing recombinant protein production in CHO cells through metabolic engineering
Frontiers in Bioengineering and Biotechnology · 03.08.2026 · 14
DOI: 10.3389/fbioe.2026.1847073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 03.08.2026. Verfasst von Lu Hou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institutes of Health Central Plains, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Henan Medical University, Xinxiang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chinese hamster ovary (CHO) cells serve as the predominant platform for producing recombinant therapeutic proteins in biopharmaceutical manufacturing, the production capacity of which relies heavily on efficient protein synthesis, folding, and secretion pathways. However, during high-density and prolonged cultivation, these cells frequently encounter bottlenecks—including excessive lactate and ammonia accumulation, redox imbalance, and endoplasmic reticulum (ER) stress—which ultimately constrain both the yield and quality of target protein. To overcome these limitations, metabolic engineering has emerged as a key strategy; through systematic modification of the CHO cellular metabolic network, it enhances recombinant protein yield, optimizes critical product qualities such as glycosylation, and improves overall process robustness. This review summarizes recent advances in CHO cell metabolic engineering, encompassing the regulation of central metabolic pathways, glycosylation engineering, cell cycle and metabolic reprogramming, culture condition optimization, byproduct accumulation control, and the application of systems biology and artificial intelligence technologies, including genome-scale metabolic modeling, machine learning-guided target prediction, and dynamic process control. These advances have significantly reduced biopharmaceutical production costs, improved scalability, and shortened time-to-market for monoclonal antibodies and other complex biologics. As the field transitions from single-gene manipulation toward multi-target, dynamic, and system-level rational design, metabolic engineering is advancing CHO cells into more efficient and intelligent “cell factories”, thereby providing sustained momentum for the industrial production of biologics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institutes of Health Central Plains, Xinxiang Key Laboratory for Tumor Drug Screening and Targeted Therapy, Henan Medical University, Xinxiang, China.
- International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Henan Medical University, Xinxiang, China.
- Henan Key Laboratory of Neurorestoratology and Protein Modification, The First Affiliated Hospital of Henan Medical University, Xinxiang, China.
Zitieren
APA
Hou, L., Li, W., Li, Z., Geng, S., Wang, T., & Zhang, J. (2026). Advancing recombinant protein production in CHO cells through metabolic engineering. Frontiers in Bioengineering and Biotechnology, 14. https://doi.org/10.3389/fbioe.2026.1847073
Vancouver
Hou L, Li W, Li Z, Geng S, Wang T, Zhang J. Advancing recombinant protein production in CHO cells through metabolic engineering. Frontiers in Bioengineering and Biotechnology. 2026;14. doi:10.3389/fbioe.2026.1847073
BibTeX
@article{Hou2026,
author = {Hou, Lu and Li, Weidong and Li, Ziyan and Geng, Shaolei and Wang, Tianyun and Zhang, Junhe},
title = {Advancing recombinant protein production in CHO cells through metabolic engineering},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2026},
volume = {14},
doi = {10.3389/fbioe.2026.1847073}
}
EUVIMED